Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
Bortezomib is the first proteasome inhibitor to treat a variety of malignancies and is currently part of the standard of care regimen for the initial treatment of patients with newly diagnosed multiple myeloma. While bortezomib is generally well tolerated, it has been associated with various side ef...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Dermatopathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2296-3529/10/3/31 |